MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

AstraZeneca plc Company Profile (NYSE:AZN)

Consensus Ratings for AstraZeneca plc (NYSE:AZN) (?)
Ratings Breakdown: 2 Sell Rating(s), 8 Hold Rating(s), 11 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $825.56 (2,863.24% upside)

Analysts' Ratings History for AstraZeneca plc (NYSE:AZN)
Show:
DateFirmActionRatingPrice TargetActions
6/25/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Leerink SwannReiterated RatingHold$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Shore CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Deutsche BankReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016Goldman SachsReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Bank of AmericaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016Drexel HamiltonInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Cantor FitzgeraldInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016HSBCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Sanford C. BernsteinLower Price Target$34.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016BarclaysUpgradeUnderweight -> Equal Weight$44.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016Credit SuisseReiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015BNP ParibasReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Nordea Equity ResearchDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015S&P Equity ResearchUpgradeBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015SwedbankUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015Berenberg BankUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Kepler Capital MarketsReiterated RatingReduceView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015Liberum CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015Panmure GordonReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015DanskeDowngradeSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2015SEB Equity ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for AstraZeneca plc (NYSE:AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q2$1.08$1.21$6.02 billion$5.84 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$1.44$1.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$1.38$1.53ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$1.73$1.81ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$1.57$1.61ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$1.64$1.71ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$1.74$1.53ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for AstraZeneca plc (NYSE:AZN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.53$1.01$0.77
Q2 20162$0.53$1.05$0.79
Q3 20162$0.56$1.11$0.84
Q4 20162$0.51$1.04$0.78
(Data provided by Zacks Investment Research)
Current Dividend Information for AstraZeneca plc (NYSE:AZN)
Annual Dividend:$0.88
Dividend Yield:3.16%
Payout Ratio:43.56%
Dividend Growth:-6.60% (3 Year Average)

Dividend History for AstraZeneca plc (NYSE:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/5/2016$0.932/17/20162/19/20163/21/2016Tweet This Announcement  Share This Announcement on StockTwits
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015Tweet This Announcement  Share This Announcement on StockTwits
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014Tweet This Announcement  Share This Announcement on StockTwits
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014Tweet This Announcement  Share This Announcement on StockTwits
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013Tweet This Announcement  Share This Announcement on StockTwits
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for AstraZeneca plc (NYSE:AZN)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for AstraZeneca plc (NYSE:AZN)
DateHeadline
06/24/16 07:54 PMAstraZeneca PLC (LON:AZN) target price held steady to GBX5,600 as disclosed today by Deutsche Bank
06/24/16 02:35 PMEx-Minister To Lead Banks' Brexit Response -
06/24/16 02:35 PMEx-Minister To Lead Banks' Brexit Response -
06/24/16 12:24 PMThe Brexit Vote Is Crushing These 3 Clinical-Stage Biotech Stocks -
06/24/16 12:24 PMThe Brexit Vote Is Crushing These 3 Clinical-Stage Biotech Stocks -
06/24/16 12:06 PMPost-Brexit Analysis: Should Investors Buy or Sell Biopharma? -
06/24/16 12:06 PMPost-Brexit Analysis: Should Investors Buy or Sell Biopharma? -
06/24/16 11:50 AMPost-Brexit opportunities in three British stocks -
06/24/16 11:50 AMPost-Brexit opportunities in three British stocks -
06/24/16 06:41 AMBrexit spells upheaval for EU and UK drug regulation - [Reuters - UK Focus] - Britain's vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA), which approves treatments for all EU countries, expected to have to relocate.
06/23/16 04:01 PMSanofi's Likely Sweetener for Medivation Panned -
06/23/16 03:00 PMAstraZeneca Likely to Grind Lower -
06/23/16 02:45 PMU.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective -
06/23/16 10:30 AMAstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
06/23/16 10:30 AMCitigroup covered (LON:AZN) AstraZeneca PLC, renewing its stock price target to GBX0 today
06/22/16 07:49 PMAstraZeneca’s Flu-Vaccine Spray Fails Again; U.S. Panel Recommends Shot
06/22/16 02:41 PMAstrazeneca PLC (NYSE:AZN) Analyst Rating Consensus - Trade Calls
06/22/16 07:30 AMTwo Movers inside Analysts Radar: Gilead Sciences, Inc. (NASDAQ:GILD) , Astrazeneca PLC (NYSE:AZN) - Street Updates
06/22/16 06:56 AMSell These 5 U.K. Stocks Now Before the Brexit Vote -
06/21/16 02:03 PM7 Pharmaceutical Stocks With Dividends Yielding More Than 3% -
06/21/16 07:27 AMLatest Analysts Tips Update: Astrazeneca PLC (NYSE:AZN) , UnitedHealth Group Incorporated (NYSE:UNH) - Street Updates
06/21/16 05:36 AMWhy earnings are expected to explode at AstraZeneca plc, Whitbread plc and Photo-Me International plc! -
06/20/16 02:42 PMFireEye Inc (NASDAQ:FEYE) & AstraZeneca plc (NYSE:AZN) Stocks on Trader's Radar - Wall Street 24
06/20/16 02:42 PMAnalyst's Stocks Ratings Trend: Astrazeneca PLC (NYSE:AZN) , Intrexon Corporation (NYSE:XON) - Street Updates
06/20/16 12:44 PMHow to Short the FTSE Ahead of The Brexit Vote -
06/19/16 11:07 PM[$$] Secret Deal Squeezes Mexico’s Drug Sector -
06/19/16 07:29 PM[$$] Secret Deal Squeezes Mexico's Drug Sector -
06/19/16 06:50 PM[$$] Secret Deal Squeezes Mexico Drug Sector -
06/17/16 10:36 AMAnalysts Rating Overview: Astrazeneca PLC (NYSE:AZN) , Baxter International Inc. (NYSE:BAX) - Street Updates
06/16/16 07:06 AMStock under Analysts' radar: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/16/16 06:21 AM3 surprisingly cheap stocks: AstraZeneca plc, Darty plc and WS Atkins plc -
06/15/16 02:47 PMComprehensive Analysis of: AstraZeneca PLC (NYSE:AZN), H&R Block, Inc. (NYSE:HRB) - Beacon Chronicle
06/15/16 07:30 AMUpdated Analysts Rating Report: Astrazeneca PLC (NYSE:AZN) , UnitedHealth Group Incorporated (NYSE:UNH) - Street Updates
06/14/16 02:40 PMHot Stock seeking Investors: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/14/16 12:35 PMCall buyers take a dose of AstraZeneca -
06/14/16 07:00 AMAstraZeneca Introduces AZhelps, an Innovative Savings and Support Program to Help Patients with Their Medicines - [Business Wire] - AstraZeneca today announced it has expanded its patient support offerings to include AZhelps, a comprehensive and unique program that helps patients manage information across all their medications, access savings offers for their AstraZeneca medicines, and easily access healthcare support through their mobile devices and on social media channels.
06/13/16 10:44 AMWhy I'd buy into the biotech revolution with AstraZeneca plc, Roche Holding Ltd. and Amgen, Inc.
06/12/16 10:32 AMPut Volume Skyrockets as AstraZeneca plc (AZN) Slides
06/11/16 10:00 AMAstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing - [Business Wire] - AstraZeneca today announced results of two pooled analyses involving more than 4,600 patients with type 2 diabetes. The two analyses, which represent AstraZeneca’s ongoing commitment to fully understanding the effects of dapagliflozin across subsets of patients with type 2 diabetes, will be presented at the 76th Scientific Sessions of the American Diabetes Association in New Orleans, June 10-14, 2016....
06/11/16 10:00 AMAstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes - [Business Wire] - AstraZeneca today announced results from a 10-week randomized, controlled, double-blind, Phase IV study investigating the quality of glucose control with BYDUREON® for injectable suspension versus placebo using continuous glucose monitoring in patients with type 2 diabetes uncontrolled on metformin.
06/10/16 02:45 PMAnalysts Suggestion Alert: Valeant Pharmaceuticals International, (VRX) , Astrazeneca PLC (AZN) - Street Updates
06/10/16 10:15 AMAstraZeneca Monetizes Anesthetics Marketing for $770 million (AZN) -
06/09/16 11:38 AMStock in the Spotlight: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/09/16 11:38 AMOne should look at these two Stocks: AstraZeneca PLC (NYSE:AZN), Monster Beverage Corporation (NASDAQ:MNST) - Beacon Chronicle
06/09/16 10:15 AM$770M deal: AstraZeneca sells rights to 7 anesthetic products -
06/08/16 03:08 PMPrice Target Update: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/08/16 11:06 AMWhat Are the Changes in AstraZeneca’s Profitability? -
06/08/16 07:00 AMAstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions - [Business Wire] - AstraZeneca and its global biologics research and development arm, MedImmune, today announced that more than 60 abstracts reporting results of the company’s research and development in diabetes have been accepted at the 76th Scientific Sessions of the American Diabetes Association in New Orleans, June 10-14, 2016.
06/07/16 08:16 PMInvestor Catching Stock: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/06/16 12:20 PMRelypsa: Largest Institutional Shareholders are Buying More Stock -
About AstraZeneca plc

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $29.29
  • 50 Day Moving Average: $28.79
  • 200 Day Moving Average: $30.04
  • P/E Ratio: 24.23
  • P/E Growth: -11.96
  • Market Cap: $70.49B
  • Current Quarter EPS Consensus Estimate: $2.45 EPS
Additional Links:
AstraZeneca plc (NYSE:AZN) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha